Ziv-aflibercept in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies) in patients ≥65.

被引：1
|
作者：
Bordonaro, Roberto
Sobrero, Alberto F.
Frassineti, Luca
Ciuffreda, Libero
Aprile, Giuseppe
Thomas, Anne L.
Moore, Yan
Zilocchi, Chiara
Dochy, Emmanuelle
Taieb, Julien
Ferry, David Raymond
机构：
[1] Garibaldi Hosp Catania, Catania, Italy
[2] IRCCS Osped San Martino IST, Genoa, Italy
[3] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
[4] Citta Salute & Sci Torino, Turin, Italy
[5] Univ Hosp Udine, Udine, Italy
[6] Univ Leicester, Leicester, Leics, England
[7] Sanofi Oncol, Cambridge, MA USA
[8] Sanofi, Milan, Italy
[9] Sanofi Oncol, Diegem, Belgium
[10] APHP, Paris, France
[11] Paris Descartes Univ, Paris, France
[12] New Cross Hosp, Wolverhampton, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.545
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
545
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Quality-of-life in patients with metastatic colorectal cancer (mCRC) treated with aflibercept and FOLFIRI - Interim results of the non-interventional AIO study QoLiTrap (AIO-LQ-0113) according to age group ≤65 and >65 years with the main focus on QoL and safety
    Piringer, G.
    Thaler, J.
    Kroening, H.
    Maintz, C.
    von Moos, R.
    Hofheinz, R. -D
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 288 - 288
  • [32] Safety and Effectiveness of Aflibercept plus Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
    Chau, Ian
    Fakih, Marwan
    Garcia-Alfonso, Pilar
    Linke, Zdenek
    Casado, Ana Ruiz
    Marques, Eduardo Polo
    Picard, Pascaline
    Celanovic, Marina
    Cartwright, Thomas
    CANCERS, 2020, 12 (03)
  • [33] Utility assessment of health-related quality of life in 2nd-line metastatic colorectal cancer patients: interim analyses of the global Aflibercept Safety and HR-QoL Program
    Sobrero, A.
    Bordonaro, R.
    Siena, S.
    Ciuffreda, L.
    Thomas, A. L.
    Taieb, J.
    Lledo, G.
    Joulain, F.
    Ferry, D. R.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S522 - S522
  • [34] Real-World Evaluation of Quality of Life, Effectiveness, and Safety of Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer: The Prospective QoLiTrap Study
    Hofheinz, Ralf-Dieter
    Anchisi, Sandro
    Grunberger, Birgit
    Derigs, Hans G.
    Zahn, Mark-Oliver
    Geffriaud-Ricouard, Christine
    Gueldner, Max
    Windemuth-Kieselbach, Christine
    Pederiva, Stefanie
    Bohanes, Pierre
    Scholten, Felicitas
    Piringer, Gudrun
    Thaler, Josef
    von Moos, Roger
    CANCERS, 2022, 14 (14)
  • [35] Panitumumab with FOLFIRI versus FOLFIRI alone: results from a randomised phase III study of second-line treatment of patients with metastatic colorectal cancer (mCRC)
    Lordick, F.
    Peeters, M.
    Price, T.
    Hotko, Y.
    Cervantes, A.
    Ducreux, M.
    Andre, T.
    Chan, E.
    Rong, A.
    Gansert, J.
    ONKOLOGIE, 2010, 33 : 3 - 3
  • [36] Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results
    Peeters, M.
    Wilson, G.
    Ducreux, M.
    Cervantes, A.
    Andre, T.
    Hotko, Y.
    Lordick, F.
    Collins, S.
    Shing, M.
    Price, T. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Song Xie
    Guoping Han
    Zhikun Fan
    Lifeng He
    Wenbing Xu
    Zhen Qin
    Medical Oncology, 2014, 31
  • [38] Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer
    Xie, Song
    Han, Guoping
    Fan, Zhikun
    He, Lifeng
    Xu, Wenbing
    Qin, Zhen
    MEDICAL ONCOLOGY, 2014, 31 (07)
  • [39] Quality of life (QoL) and therapy management in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): Interim results of the noninterventional QoLiTrap-study.
    Hofheinz, Ralf
    Thaler, Josef
    Von Moos, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [40] Results From VELOUR, a Phase 3 Study of Aflibercept (A) Versus Placebo (pbo) in Combination with FOLFIRI for the Treatment of Patients (pt) with Previously Treated Metastatic Colorectal Cancer (MCRC)
    Tabernero, J.
    Van Cutsem, E.
    Lakomy, R.
    Prausova, J.
    Ruff, P.
    Van Hazel, G.
    Moiseyenko, V.
    Ferry, D.
    McKendrick, J.
    Soussan-Lazard, K.
    Boelle, E.
    Allegra, C.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : 5 - 5
12345